{
    "nct_id": "NCT01354691",
    "title": "A 6-Month Prospective, Multi-Center, Double-Blind, Placebo-Controlled, Randomized, Adaptive-Trial-Design Study to Evaluate the Safety and Efficacy of 80mg b.i.d Ladostigil in Patients With Mild to Moderate Probable Alzheimer's Disease",
    "status": "COMPLETED",
    "last_update_time": "2020-07-13",
    "description_brief": "For many, Alzheimer's disease is the number one medical issue facing our aging society. It is a late onset neurodegenerative disease, frequently under diagnosed, that impairs memory and cognitive performance. There are no known treatments that can either prevent or reverse its progression. Consequently, there still remains a need to evaluate treatments which can better stabilize the symptoms of this disease. These symptoms frequently include decreased functional capacity and negative psychological attributes (e,g, depression, anxiety) in association with the memory and cognition deficits. This current study is being done to assess an investigational compound that has been designed to not only improved the cognitive status of affected patients but to also better manage all symptoms. Hence, the ultimate goal is to provide patients with an improved quality of life by slowing the progression of this neurodegenerative disease",
    "description_detailed": "This is a phase II, proof of concept study to evaluate the safety and efficacy of the investigational compound ladostigil versus placebo in mild to moderate Alzheimer's disease patients. The randomized, double-blind, placebo-controlled phase of the trial will be 26 weeks in duration and will involve two cohorts (i.e. one arm receiving ladostigil and one arm receiving placebo). After the initial 26 week period, all participating subjects will receive 26 weeks of treatment with ladostigil (i.e. the open label phase). A total of five territories will be participating in this trial. These include Austria, Croatia, Germany, Serbia and Spain.",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": {
        "participantFlowModule": {
            "groups": [
                {
                    "id": "FG000",
                    "title": "Ladostigil Hemitartrate",
                    "description": "Ladostigil capsules 80 mg\n\nladostigil hemitartrate: Final dosage strength of 80mg b.i.d will begin at Day 22 following a 21 day dose escalation phase involving 40mg and 60mg b.i.d dosage strengths. Oral, solid dosage."
                },
                {
                    "id": "FG001",
                    "title": "Placebo",
                    "description": "Placebo capsules\n\nladostigil hemitartrate: Final dosage strength of 80mg b.i.d will begin at Day 22 following a 21 day dose escalation phase involving 40mg and 60mg b.i.d dosage strengths. Oral, solid dosage."
                }
            ],
            "periods": [
                {
                    "title": "Overall Study",
                    "milestones": [
                        {
                            "type": "STARTED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "101"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "99"
                                }
                            ]
                        },
                        {
                            "type": "ITT",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "99"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "96"
                                }
                            ]
                        },
                        {
                            "type": "PP",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "79"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "75"
                                }
                            ]
                        },
                        {
                            "type": "COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "80"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "77"
                                }
                            ]
                        },
                        {
                            "type": "NOT COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "21"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "22"
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "baselineCharacteristicsModule": {
            "groups": [
                {
                    "id": "BG000",
                    "title": "Ladostigil Hemitartrate",
                    "description": "Ladostigil capsules 80 mg\n\nladostigil hemitartrate: Final dosage strength of 80mg b.i.d will begin at Day 22 following a 21 day dose escalation phase involving 40mg and 60mg b.i.d dosage strengths. Oral, solid dosage."
                },
                {
                    "id": "BG001",
                    "title": "Placebo",
                    "description": "Placebo capsules\n\nladostigil hemitartrate: Final dosage strength of 80mg b.i.d will begin at Day 22 following a 21 day dose escalation phase involving 40mg and 60mg b.i.d dosage strengths. Oral, solid dosage."
                },
                {
                    "id": "BG002",
                    "title": "Total",
                    "description": "Total of all reporting groups"
                }
            ],
            "denoms": [
                {
                    "units": "Participants",
                    "counts": [
                        {
                            "groupId": "BG000",
                            "value": "101"
                        },
                        {
                            "groupId": "BG001",
                            "value": "99"
                        },
                        {
                            "groupId": "BG002",
                            "value": "200"
                        }
                    ]
                }
            ],
            "measures": [
                {
                    "title": "Age, Categorical",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "<=18 years",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Between 18 and 65 years",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "15"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "15"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "30"
                                        }
                                    ]
                                },
                                {
                                    "title": ">=65 years",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "86"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "84"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "170"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Age, Continuous",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "years",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "74.25",
                                            "spread": "6.73"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "74.28",
                                            "spread": "6.92"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "74.26",
                                            "spread": "6.8"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Sex: Female, Male",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "Female",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "56"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "60"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "116"
                                        }
                                    ]
                                },
                                {
                                    "title": "Male",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "45"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "39"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "84"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Race/Ethnicity, Customized",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "title": "Ethnicity",
                            "categories": [
                                {
                                    "title": "White or Caucasian",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "101"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "99"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "200"
                                        }
                                    ]
                                },
                                {
                                    "title": "Other",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Region of Enrollment",
                    "paramType": "NUMBER",
                    "unitOfMeasure": "participants",
                    "classes": [
                        {
                            "title": "Austria",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "28"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "27"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "55"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Serbia",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "4"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "2"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "6"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Germany",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "9"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "8"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "17"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Croatia",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "44"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "45"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "89"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Spain",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "16"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "17"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "33"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "outcomeMeasuresModule": {
            "outcomeMeasures": [
                {
                    "type": "PRIMARY",
                    "title": "ADAS-Cog: Alzheimer's Disease Assessment Scale-Cognitive Subscale",
                    "description": "Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) is a brief neuropsychological assessment used to assess the severity of cognitive symptoms of dementia, The ADAS-Cog consist of 11 questions:\n\nWord Recall Task Naming Objects and Fingers Following Commands Constructional Praxis Ideational Praxis Orientation Word Recognition Task Remembering Test Directions Spoken Language Comprehension Word-Finding Difficulty\n\nItem scores are summed.\n\nLow total scores indicate better cognitive performance. Minimum score 0 is best and maximum is 70 - worst.\n\nFor the purposes of analyses the change from baseline is computed to each administration of the test.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "score on scale - baseline to endpoint",
                    "timeFrame": "26 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Ladostigil Hemitartrate",
                            "description": "Ladostigil capsules 80 mg\n\nladostigil hemitartrate: Final dosage strength of 80mg b.i.d will begin at Day 22 following a 21 day dose escalation phase involving 40mg and 60mg b.i.d dosage strengths. Oral, solid dosage."
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "Placebo capsules\n\nladostigil hemitartrate: Final dosage strength of 80mg b.i.d will begin at Day 22 following a 21 day dose escalation phase involving 40mg and 60mg b.i.d dosage strengths. Oral, solid dosage."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "99"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "96"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-.27",
                                            "spread": "5.41"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0.19",
                                            "spread": "5.15"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "nonInferiorityType": "SUPERIORITY",
                            "pValue": "<0.67",
                            "statisticalMethod": "ANCOVA"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Neuropsychiatric Inventory (NPI)",
                    "description": "The Neuropsychiatric Inventory (NPI) was developed to assess psychopathology in dementia patients. It evaluates 12 neuropsychiatric disturbances common in dementia: delusions, hallucinations, agitation, dysphoria, anxiety, apathy, irritability, euphoria, disinhibition, aberrant motor behavior, night-time behavior disturbances, and appetite and eating abnormalities. The severity and frequency of each neuropsychiatric symptom are rated on the basis of scripted questions administered to the patient's caregiver. Higher the score the more disturbed, lower score is thus better. Minimum score is 0 and maximum is 80.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "score on scale - baseline to endpoint",
                    "timeFrame": "52 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Ladostigil Hemitartrate",
                            "description": "Ladostigil capsules 80 mg\n\nladostigil hemitartrate: Final dosage strength of 80mg b.i.d will begin at Day 22 following a 21 day dose escalation phase involving 40mg and 60mg b.i.d dosage strengths. Oral, solid dosage."
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "Placebo capsules\n\nladostigil hemitartrate: Final dosage strength of 80mg b.i.d will begin at Day 22 following a 21 day dose escalation phase involving 40mg and 60mg b.i.d dosage strengths. Oral, solid dosage."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "99"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "96"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "2.51",
                                            "spread": "11.27"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0.66",
                                            "spread": "7.90"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "nonInferiorityType": "SUPERIORITY",
                            "pValue": "<0.21",
                            "statisticalMethod": "ANCOVA"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Cornell Scale for Depression in Dementia (CSDD)",
                    "description": "The Cornell Scale for Depression in Dementia (CSDD) was developed specifically to assess signs and symptoms of major depression in dementia on the basis of a semi-structured interview of a qualified informant. The CSDD evaluates a broad spectrum of depressive signs and synptoms and includes items from other depression scales. Information is obtained from interview of the caregiver as well as from direct observation and interview of the patient CSDD is a 19 item scale assessing depressive status. Higher score more depression. The scale ranges from 0-no depression to 38 maximum depression.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "score on scale - baseline to endpoint",
                    "timeFrame": "52 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Ladostigil Hemitartrate",
                            "description": "Ladostigil capsules 80 mg\n\nladostigil hemitartrate: Final dosage strength of 80mg b.i.d will begin at Day 22 following a 21 day dose escalation phase involving 40mg and 60mg b.i.d dosage strengths. Oral, solid dosage."
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "Placebo capsules\n\nladostigil hemitartrate: Final dosage strength of 80mg b.i.d will begin at Day 22 following a 21 day dose escalation phase involving 40mg and 60mg b.i.d dosage strengths. Oral, solid dosage."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "93"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "86"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.08",
                                            "spread": "2.81"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.45",
                                            "spread": "3.28"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "nonInferiorityType": "SUPERIORITY",
                            "pValue": "<0.78",
                            "statisticalMethod": "ANCOVA"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)",
                    "description": "The Activities of Daily Living ADCS-ADL is a caregiver-based ADL scale composed of 23 items developed for use in dementia clinical trials. It is designed to assess the patient's performance of both basic and instrumental activities of daily living such as those necessary for personal care, communicating and interacting with other people, maintaining a household, conducting hobbies and interests as well as making judgments and decisions. For each ADL, the caregiver is asked whether the patient attempted the activity during the past four weeks. If the answer is positive, the caregiver is then asked to choose the single most accurate definition of the patient's level of performance. Assessment of functional activity status is a 23 item scale measuring impairment in functioning. The scale total score ranges from 0-profound impairment to 30 normal functioning (no impairments)",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "score on scale - baseline to endpoint",
                    "timeFrame": "52 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Ladostigil Hemitartrate",
                            "description": "Ladostigil capsules 80 mg\n\nladostigil hemitartrate: Final dosage strength of 80mg b.i.d will begin at Day 22 following a 21 day dose escalation phase involving 40mg and 60mg b.i.d dosage strengths. Oral, solid dosage."
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "Placebo capsules\n\nladostigil hemitartrate: Final dosage strength of 80mg b.i.d will begin at Day 22 following a 21 day dose escalation phase involving 40mg and 60mg b.i.d dosage strengths. Oral, solid dosage."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "99"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "96"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-1.88",
                                            "spread": "9.54"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-1.57",
                                            "spread": "7.72"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "nonInferiorityType": "SUPERIORITY",
                            "pValue": "=0.83",
                            "statisticalMethod": "ANCOVA"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Mini-Mental State Examination",
                    "description": "The MMSE is a frequently used screening instrument for AD drug studies. The instrument provides for evaluation of orientation, memory, attention, concentration, naming, repetition, comprehension, ability to create a sentence and to copy two intersecting polygons. This examination is frequently used by physicians in the original diagnosis of AD, and in its subsequent progression, because it can be easily performed in the routine care of patients. A lower score indicates more cognitive impairment. The highest (best) score is 30. The Mini-Mental State Examination, MMSE, is a 30-point questionnaire measures cognitive impairment to screen for dementia. Items are totaled. The scale ranges from 0-most impairment to 30 (normal) no impairment.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "change in score - baseline to endpoint",
                    "timeFrame": "52 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Ladostigil Hemitartrate",
                            "description": "Ladostigil capsules 80 mg\n\nladostigil hemitartrate: Final dosage strength of 80mg b.i.d will begin at Day 22 following a 21 day dose escalation phase involving 40mg and 60mg b.i.d dosage strengths. Oral, solid dosage."
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo",
                            "description": "Placebo capsules\n\nladostigil hemitartrate: Final dosage strength of 80mg b.i.d will begin at Day 22 following a 21 day dose escalation phase involving 40mg and 60mg b.i.d dosage strengths. Oral, solid dosage."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "99"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "96"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.80",
                                            "spread": "2.73"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0.60",
                                            "spread": "2.59"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "nonInferiorityType": "SUPERIORITY",
                            "pValue": "=.77",
                            "statisticalMethod": "ANCOVA"
                        }
                    ]
                }
            ]
        },
        "adverseEventsModule": {
            "frequencyThreshold": "5",
            "timeFrame": "26 weeks",
            "description": "Enrolled patients Ladostigil 101(100.0%) Placebo 99(100.0%) ITT Population Ladostigil 99(98.02%) Placebo 96(96.97%) PP Population Ladostigil 79(78.22%) Placebo 75(75.76%) Safety Population Ladostigil 100(99.01%) Placebo 98(98.99%)\n\none patient discontinued the study in each group before administration of drug that is why the Safety Population is: Ladostigil 100(99.01%) Placebo 98(98.99%)",
            "eventGroups": [
                {
                    "id": "EG000",
                    "title": "Ladostigil Hemitartrate",
                    "description": "Ladostigil capsules 80 mg\n\nladostigil hemitartrate: Final dosage strength of 80mg b.i.d will begin at Day 22 following a 21 day dose escalation phase involving 40mg and 60mg b.i.d dosage strengths. Oral, solid dosage.",
                    "deathsNumAffected": 0,
                    "deathsNumAtRisk": 100,
                    "seriousNumAffected": 7,
                    "seriousNumAtRisk": 100,
                    "otherNumAffected": 11,
                    "otherNumAtRisk": 100
                },
                {
                    "id": "EG001",
                    "title": "Placebo",
                    "description": "Placebo capsules\n\nladostigil hemitartrate: Final dosage strength of 80mg b.i.d will begin at Day 22 following a 21 day dose escalation phase involving 40mg and 60mg b.i.d dosage strengths. Oral, solid dosage.",
                    "deathsNumAffected": 2,
                    "deathsNumAtRisk": 98,
                    "seriousNumAffected": 7,
                    "seriousNumAtRisk": 98,
                    "otherNumAffected": 2,
                    "otherNumAtRisk": 98
                }
            ],
            "seriousEvents": [
                {
                    "term": "ACUTE MYOCARDIAL INFARCT",
                    "organSystem": "Cardiac disorders",
                    "sourceVocabulary": "MedDRA (10.0)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 100
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 98
                        }
                    ]
                },
                {
                    "term": "Brain Stroke",
                    "organSystem": "Vascular disorders",
                    "sourceVocabulary": "MedDRA (10.0)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 100
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 98
                        }
                    ]
                },
                {
                    "term": "Elbow Fracture",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "sourceVocabulary": "MedDRA (10.0)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 100
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 98
                        }
                    ]
                },
                {
                    "term": "Femur fracture subtrochan",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "sourceVocabulary": "MedDRA (10.0)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 100
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 98
                        }
                    ]
                },
                {
                    "term": "Sick Sinus Syndrome",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "sourceVocabulary": "MedDRA (10.0)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 100
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 98
                        }
                    ]
                },
                {
                    "term": "Sun Stroke",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA (10.0)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 100
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 98
                        }
                    ]
                },
                {
                    "term": "Thoracic Pain",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "sourceVocabulary": "MedDRA (10.0)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 100
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 98
                        }
                    ]
                },
                {
                    "term": "Acute Cholecystitis",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA (10.0)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 100
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 98
                        }
                    ]
                },
                {
                    "term": "Arthritis left ankle",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "sourceVocabulary": "MedDRA (10.0)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 100
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 98
                        }
                    ]
                },
                {
                    "term": "Obstipation",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA (10.0)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 100
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 98
                        }
                    ]
                },
                {
                    "term": "Pneunomia",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "sourceVocabulary": "MedDRA (10.0)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 100
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 98
                        }
                    ]
                },
                {
                    "term": "POLYTRAUMATISM",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA (10.0)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 100
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 98
                        }
                    ]
                },
                {
                    "term": "Urinary Infection",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "MedDRA (10.0)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 100
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 2,
                            "numAffected": 2,
                            "numAtRisk": 98
                        }
                    ]
                }
            ],
            "otherEvents": [
                {
                    "term": "Diarrhoea",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA (10.0)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 6,
                            "numAffected": 6,
                            "numAtRisk": 100
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 3,
                            "numAffected": 2,
                            "numAtRisk": 98
                        }
                    ]
                },
                {
                    "term": "Essential hypertension",
                    "organSystem": "Cardiac disorders",
                    "sourceVocabulary": "MedDRA (10.0)",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 6,
                            "numAffected": 6,
                            "numAtRisk": 100
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 98
                        }
                    ]
                }
            ]
        },
        "moreInfoModule": {
            "certainAgreement": {
                "piSponsorEmployee": false,
                "restrictiveAgreement": false
            },
            "pointOfContact": {
                "title": "Jonathan Rabinowitz, PhD",
                "organization": "Bar Ilan University",
                "email": "jonathan.rabinowitz@biu.ac.il"
            }
        }
    },
    "target_category": "disease-targeted small molecule",
    "drug": [
        "Ladostigil (TV-3326) \u2014 investigational small-molecule multimodal agent, 80 mg b.i.d"
    ],
    "placebo": [
        "Placebo (placebo-controlled arm)"
    ],
    "explanation_target": [
        "Reason: The trial tests ladostigil, which is a small-molecule, orally administered multimodal agent designed to inhibit cholinesterases and brain-selective monoamine oxidases and has neuroprotective actions (including effects on APP processing/amyloid pathways). These properties indicate both symptomatic cognitive action and direct effects on Alzheimer's-related pathology. \ue200cite\ue202turn0search6\ue202turn0search4\ue202turn0search2\ue201.",
        "Act: The trial listing explicitly names the intervention as 80 mg b.i.d. ladostigil in a randomized, double-blind, placebo-controlled Phase 2 study (NCT01354691). The protocol description states goals of improving cognitive status, managing neuropsychiatric symptoms, and slowing disease progression. \ue200cite\ue202turn0search1\ue202turn0search1\ue201.",
        "Supporting evidence: Clinical publications and reviews describe ladostigil as a small-molecule dual acetylcholinesterase/butyrylcholinesterase and brain-selective MAO inhibitor with neuroprotective effects and potential to modulate APP processing and brain atrophy measures in trials. (See Neurology/PubMed trial reports and mechanistic reviews). \ue200cite\ue202turn0search0\ue202turn0search5\ue202turn0search3\ue201.",
        "Reflect: Given ladostigil is a synthetic small molecule (not a biologic) and its intended actions include targeting Alzheimer-related mechanisms (APP/amyloid-related processing, neuroprotection) in addition to symptomatic cognitive and mood effects, the most appropriate category is 'disease-targeted small molecule'. There is some overlap with 'cognitive enhancer' (symptomatic cholinergic/antidepressant effects), but the drug\u2019s described disease-modifying mechanisms support the disease-targeted small molecule classification. \ue200cite\ue202turn0search6\ue202turn0search2\ue201."
    ],
    "agent_type": "R) Multi-target",
    "explanation_agent": [
        "Reason: The investigational drug ladostigil (TV-3326) is a small-molecule, multimodal compound with multiple mechanistic actions \u2014 cholinesterase (AChE/BChE) inhibition, brain-selective monoamine oxidase (MAO\u2011A/MAO\u2011B) inhibition, and reported neuroprotective effects including regulation of APP processing and reductions in markers of neurodegeneration/atrophy. These diverse mechanisms span symptomatic neurotransmitter modulation and potential disease-modifying pathways (APP/amyloid processing, anti-apoptotic/antioxidant and neurotrophic effects), so the intervention does not map cleanly to a single CADRO class. \ue200cite\ue202turn0search5\ue202turn0search4\ue202turn0search3\ue201",
        "Act: Based on the trial listing (NCT01354691) and mechanistic reviews, ladostigil was administered as an 80 mg b.i.d. oral small molecule in a Phase 2 randomized, double\u2011blind, placebo\u2011controlled study in mild\u2013moderate AD; the compound\u2019s described activities explicitly include cholinesterase and brain\u2011selective MAO inhibition plus regulation of APP processing and neuroprotection. Because the drug intentionally targets multiple biological processes relevant to AD (neurotransmitter enzymes, APP/amyloid-related processing, neuroprotective/anti\u2011atrophy actions), the most appropriate CADRO assignment is R) Multi-target. \ue200cite\ue202turn0search0\ue202turn0search6\ue202turn0search7\ue201",
        "Reflect: I verified that the literature and trial registry consistently describe ladostigil as multimodal (dual cholinesterase and MAO inhibition) with additional effects on APP processing, neuroprotection, and reductions in brain atrophy in clinical/animal studies \u2014 i.e., multiple distinct targets/pathways are involved. Given CADRO guidance to use 'Multi-target' when multiple mechanisms are indicated, R) Multi-target best fits. If you prefer a single-focus mapping, the drug also overlaps with D) Neurotransmitter-related symptomatic mechanisms and M) Synaptic Plasticity/Neuroprotection and A) Amyloid beta (via APP processing), but none alone capture the compound\u2019s multimodal profile. \ue200cite\ue202turn0search2\ue202turn0search1\ue201",
        "Web search results used (brief):",
        "- Clinical trial record for NCT01354691 (Phase 2 ladostigil 80 mg b.i.d): trial design, dose, and completion status. \ue200cite\ue202turn0search0\ue201",
        "- PubMed (AAN) trial of ladostigil in MCI: clinical outcomes and MRI atrophy findings. \ue200cite\ue202turn0search1\ue201",
        "- Reviews and mechanistic studies describing dual cholinesterase and brain\u2011selective MAO inhibition, neuroprotective activity, and APP processing effects (multiple PubMed/PMC reviews). \ue200cite\ue202turn0search5\ue202turn0search7\ue202turn0search4\ue201"
    ]
}